Comparison of Enteral versus Intravenous Potassium Supplementation in hypokalaemia in postcardiac surgery paediatric cardiac intensive care patients: prospective open label randomised control trial (EIPS)
Quratulain Merchant, Naveed Ur Rehman Siddiqui, Amina Rehmat, Muneer Amanullah, Anwar Ul Haq, Babar Hasan, Quratulain Merchant, Naveed Ur Rehman Siddiqui, Amina Rehmat, Muneer Amanullah, Anwar Ul Haq, Babar Hasan
Abstract
Background: Hypokalaemia is frequently encountered in the daily clinical practices of a paediatric cardiac intensive care unit (PCICU). It is a strong independent predictor of mortality in patients with heart failure. Thus, prompt potassium replacement therapy holds pivotal importance in therapy for hypokalaemia. Although intravenous potassium replacement (IVPR) in hypokalaemia is the preferred route in most intensive care settings, it is associated with known safety risks and can lead to arrhythmias, cardiac arrest and death if inappropriately administered. Enteral potassium replacement (EPR), with its superior safety profile, may be a better alternative to IVPR.
Outcome: Primary outcome To compare the efficacy EPR and IVPR for treatment of hypokalaemia. Secondary outcome measures include a comparison of adverse effects (hyperkalaemia, diarrhoea, gastrointestinal bleeds, nausea and vomiting) after EPR and IVPR and a comparison of the number of dose/s required to achieve resolution of hypokalaemia for each episode of hypokalaemia.
Methods and analysis: The Enteral Versus Intravenous Potassium Supplementation trial is designed as a randomised, controlled, non-blinded trial with two arms. Intervention arms will be block randomised on alternate weeks for IVPR and EPR. Recruited patients will receive treatment accordingly. For analysis, the percentage change in serum potassium levels in mEq/L after each event of potassium replacement in both arms will be used as an end point to compare the efficacy EPR and IVPR for treatment of hypokalaemia.
Study setting: The study will be conducted at the PCICU at the Aga Khan University Hospital, Karachi.
Ethics and dissemination: This study has been approved by the Ethics Review Committee and Clinical Trials Unit at The Aga Khan University with respect to scientific content and compliance with applicable research and human subjects regulations.
Trial registration number: This trial is registered at Clinical Trials.Gov.
Registration number: NCT02015962.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Figures
References
- Schaber DE, Uden DL, Stone FM, et al. Intravenous KCl supplementation in pediatric cardiac surgical patients. Pediatr Cardiol 1985;6:25–8
- Schulman M, Narins RG. Hypokalemia and cardiovascular disease. Am J Cardiol 1990;65:4E–9E; discussion 22E-23E
- Gennari FJ. Hypokalemia. N Engl J Med 1998;339:451–8
- Podrid PJ. Potassium and ventricular arrhythmias. Am J Cardiol 1990;65:33E–44E; discussion 52E
- Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 1994;128:564–74
- Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol 2004;43:155–61
- Schaber DE, Uden DL, Stone FM, et al. Intravenous KCl supplementation in pediatric cardiac surgical patients. Pediatr Cardiol 1985;6:25–8
- Moffett BS, McDade E, Rossano JW, et al. Enteral potassium supplementation in a pediatric cardiac intensive care unit: evaluation of a practice change. Pediatr Crit Care Med 2011;12:552–4
- Institute for Safe Medication Practices. (accessed 2 Aug 2009)
- Institute for Safe Medication Practices. (accessed 2 Aug 2009)
- Lacy CF, Armstrong LL, Goldman MP. ‘Lexi-Comp's drug information handbook’. 13 edn. Hudson: Lexi Comp 2006:1225–6
Source: PubMed